knowcompoundsFolic acidfindings
Every finding on folic acid
22 findings, by evidence strength
22 shown
- Forced expiratory volume in one second (FEV1)Moved: no difference foundEvidence: ModeratePaper: PMID 288846032018
- Who
- Children aged 7 to 10 years at the mid-childhood visit in the Project Viva prospective birth cohort (Massachusetts), by maternal first-trimester folic acid intake from food and supplements (quartiles); whole cohort, not sex-stratified
- Dose studied
- maternal intake from food plus supplements, FFQ, quartiles
There was no association between maternal folic acid intake and post-FEV1 in the total cohort of children.”
Quoted verbatim from Folic Acid in Pregnancy and Childhood Asthma: A US Cohort.cohortPermalink - Autism spectrum disorder diagnosis (offspring)Moved: lowersEffect, as reportedOR0.66[0.55 to 0.79]Evidence: ModeratePaper: PMID 412285122025
- Who
- Offspring of mothers who did or did not take folic acid before and/or during pregnancy, pooled from 24 non-randomised studies (case-control, cohort and cross-sectional)
- Dose studied
- not reported
The MA indicated that maternal folic acid supplementation is associated with a significant reduction in the risk of offspring ASD (pooled OR = 0.66, 95% CI: 0.55–0.79), as shown in the forest plot.”
Quoted verbatim from The Effect of Maternal Folic Acid Supplementation on Neurodevelopmental Disorders in Offspring: An Umbrella Review of Systematic Reviews and Meta-Analyses.meta-analysisPermalink - Montreal Cognitive Assessment total scoreMoved: raisesEvidence: ModeratePaper: PMID 409459662026
- Who
- Adults aged 40-80 years with cerebral small vessel disease-related cognitive impairment, intention-to-treat analysis at 6 months
- Dose studied
- 0.4 mg tablet, two tablets daily, six months
Specifically, total MoCA score (ITT: β = 1.27; 95 % CI = 0.52, 2.03; PP: β = 1.15; 95 % CI = 0.37, 1.93) and total MMSE score (ITT: β = 0.76; 95 % CI = 0.14, 1.39; PP: β = 0.65; 95 % CI = 0.02, 1.28) were improved among patients with CSVD-CI in the FA intervention group compared with those in the placebo group at follow-ups after adjustment of potential confounders.”
Quoted verbatim from Folic acid supplementation improves cognitive function in participants with cerebral small vascular disease-related cognitive impairment: a randomized controlled trial.RCTPermalink - Mini-Mental State Examination total scoreMoved: raisesEvidence: ModeratePaper: PMID 409459662026
- Who
- Adults aged 40-80 years with cerebral small vessel disease-related cognitive impairment, intention-to-treat analysis at 6 months
- Dose studied
- 0.4 mg tablet, two tablets daily, six months
Specifically, total MoCA score (ITT: β = 1.27; 95 % CI = 0.52, 2.03; PP: β = 1.15; 95 % CI = 0.37, 1.93) and total MMSE score (ITT: β = 0.76; 95 % CI = 0.14, 1.39; PP: β = 0.65; 95 % CI = 0.02, 1.28) were improved among patients with CSVD-CI in the FA intervention group compared with those in the placebo group at follow-ups after adjustment of potential confounders.”
Quoted verbatim from Folic acid supplementation improves cognitive function in participants with cerebral small vascular disease-related cognitive impairment: a randomized controlled trial.RCTPermalink - Colorectal cancer incidenceMoved: no difference foundEffect, as reportedRR1[0.82 to 1.22]Evidence: Moderatereplicated ×1Paper: PMID 261317632015
- Who
- Participants in eight randomized controlled trials of folic acid, total population
- Dose studied
- not reported
The results suggested that folic acid treatment was not associated with colorectal cancer risk in the total population (relative risk [RR] = 1.00, 95% confidence interval [CI] = 0.82-1.22, P = 0.974).”
Quoted verbatim from Folic acid supplements and colorectal cancer risk: meta-analysis of randomized controlled trials.meta-analysisPermalink - Preterm birth incidenceMoved: no difference foundEvidence: Moderatereplicated ×1Paper: PMID 355775772022An author is affiliated with a producer
- Who
- Norwegian MoBa cohort pregnancies of women with epilepsy not using antiseizure medication, and of women without epilepsy; periconceptional folic acid use versus none
- Dose studied
- not reported
We found no association between folic acid supplement and preterm birth in the Epilepsy without ASM group or in the No epilepsy group (Table 2).”
Quoted verbatim from Folic Acid and Risk of Preterm Birth, Preeclampsia, and Fetal Growth Restriction Among Women With Epilepsy: A Prospective Cohort Study.cohortPermalink - All-site cancer incidencecontestedMoved: no difference foundEffect, as reportedRR1.06[0.99 to 1.13]Evidence: ModeratePaper: PMID 233525522013An author is affiliated with a producer
- Who
- Adults in 13 randomised trials of folic acid versus placebo (10 trials in people with or at high risk of cardiovascular disease, 3 in patients with prior colorectal adenoma); mean age 64 years
- Dose studied
- 0.5 to 5 mg folic acid daily in all trials but one (40 mg daily); one trial compared 2.5 mg with 0.02 mg
Allocation to folic acid treatment did not have any statistically significant effect on overall cancer incidence, with 1904 (7.7%) first events in 24,799 participants allocated folic acid versus 1809 (7.3%) in 24,822 allocated control (RR 1.06; 95% CI 0.99–1.13, p=0.10: Figure 1).”
Quoted verbatim from Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals.meta-analysisPermalink - All-cause mortalityMoved: no difference foundEvidence: ModeratePaper: PMID 364324342022
- Who
- 1553 postmenopausal women in the Women's Health Initiative diagnosed with invasive breast cancer, who completed a food frequency questionnaire before and after diagnosis; change in dietary folate/folic acid intake from before to after diagnosis, mean follow-up 16.1 years
- Dose studied
- not reported
Furthermore, changes in dietary folate/folic acid or vitamin B12 intake were not associated with all-cause or breast cancer mortality after adjustment of other prognostic and dietary factors (Table 2 and Table 3).”
Quoted verbatim from Changes in Dietary Intake of Methionine, Folate/Folic Acid and Vitamin B12 and Survival in Postmenopausal Women with Breast Cancer: A Prospective Cohort Study.cohortPermalink - Lung cancer incidenceMoved: no difference foundEffect, as reportedHR1.09[0.91 to 1.3]Evidence: ModeratePaper: PMID 308384352020
- Who
- Black and white adults aged 40-79 in the Southern Community Cohort Study, southeastern US; dietary intake of synthetic folic acid from foods (fortification), highest vs lowest quartile, fully-adjusted model
- Dose studied
- dietary food folic acid intake per 1,000 kcal, highest vs lowest quartile (FFQ)
When we further investigated natural dietary folate (“food folate”) and synthetic folic acid (“food folic acid”) intakes from foods separately (Table 4), neither of them were associated with lung cancer risk (food folate: HR=1.00, 95% CI=0.84–1.19, P-trend=0.79; food folic acid: HR=1.09, 95% CI=0.91–1.30, P-trend=0.44).”
Quoted verbatim from Food intake of folate, folic acid and other B vitamins with lung cancer risk in a low-income population in the Southeastern United States.cohortPermalink - Gestational age at delivery (length of gestation)Moved: no difference foundEvidence: ModeratePaper: PMID 387834132024Industry funded
- Who
- Pregnant women in South Australia randomised at 12-16 weeks gestation to a prenatal multivitamin and mineral supplement with 800 µg/day folic acid or the same formulation without folic acid, until 36 weeks; multivitamin and mineral content identical in both arms
- Dose studied
- 800 µg/day folic acid versus 0 µg/day, in a prenatal multivitamin and mineral supplement
There were no significant differences between the groups for birth gestational age, weight and length, except for head circumference, which was lower in the 0 µg FA/day supplement group compared to the 800 µg FA/day group (mean difference: −0.9 cm; 95% CI, −1.8, −0.1, p = 0.04) (Table 2).”
Quoted verbatim from Maternal serum unmetabolized folic acid concentration following multivitamin and mineral supplementation with or without folic acid after 12 weeks gestation: A randomized controlled trial.RCTPermalink - Interleukin-6 concentrationMoved: no difference foundEffect, as reportedSMD−0.04[−1.08 to 1.01]Evidence: ModeratePaper: PMID 386493472024
- Who
- Adults with type 2 diabetes mellitus; two randomized placebo-controlled trials pooled for IL-6
- Dose studied
- not reported
Only two trials assessed the effect of folate on IL-6; the evidence from the random-effect meta-analysis showed a small effect size, and this also not significant, SMD = −0.04, 95%CI (−1.08, 1.01), p = 0.95.”
Quoted verbatim from Folic acid supplementation on inflammation and homocysteine in type 2 diabetes mellitus: systematic review and meta-analysis of randomized controlled trials.meta-analysisPermalink - Fasting blood glucoseMoved: lowersEffect, as reportedMD−2.17[−3.69 to −0.65]Evidence: ModeratePaper: PMID 343718672021
- Who
- Adults in randomized controlled trials of folic acid supplementation (pooled, 24 studies)
- Dose studied
- not reported
Results revealed significant reductions in FBG (weighted mean difference (WMD): -2.17 mg/dL, 95% CI: -3.69, -0.65, p = 0.005), fasting insulin (WMD: -1.63 pmol/L, 95% CI: -2.53, -0.73, p < 0.001), and HOMA-IR (WMD: -0.40, 95% CI: -0.70, -0.09, p = 0.011) following folic acid supplementation.”
Quoted verbatim from Folic Acid Supplementation Improves Glycemic Control for Diabetes Prevention and Management: A Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials.meta-analysisPermalink - C-reactive protein concentrationMoved: lowersEffect, as reportedMD−0.59[−0.85 to −0.33]Evidence: ModeratePaper: PMID 343718372021
- Who
- Participants in 12 randomized controlled trials of folic acid supplementation versus placebo (pooled)
- Dose studied
- not reported
The pooled analysis revealed that serum concentrations of CRP (WMD: -0.59 mg/L, 95% CI -0.85 to -0.33, p < 0.001) were significantly reduced following folic acid supplementation compared to placebo, but did not affect serum concentrations of IL-6 (WMD: -0.12, 95% CI -0.95 to 0.72 pg/mL, p = 0.780) or TNF-α (WMD: -0.18, 95% CI -0.86 to 0.49 pg/mL, p = 0.594).”
Quoted verbatim from Effects of Folic Acid Supplementation on Inflammatory Markers: A Grade-Assessed Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials.meta-analysisPermalink - Colorectal cancer incidenceMoved: no difference foundEffect, as reportedOR0.95[0.59 to 1.53]Evidence: Limitedreplicated ×1Paper: PMID 321404322020
- Who
- Women aged 40-80 living in rural East Azerbaijan, Iran; 135 colorectal cancer cases matched to 270 controls; any history of folic acid supplement intake vs none
- Dose studied
- folic acid supplement 0.4 mg/day (2.8 mg/week), prescribed to women of child-bearing age; recorded history of intake
There was no significant association between folic acid supplementation and colorectal cancer risk (OR 0.95, 95% CI 0.59–1.53) for those with history of folic acid intake compared to no history of intake.”
Quoted verbatim from Folic Acid Supplement Intake and Risk of Colorectal Cancer in Women; A Case Control Study.case-controlPermalink - Incidence of cardiovascular disease (composite)Moved: lowersEffect, as reportedRR0.85[0.76 to 0.96]Evidence: Very limitedPaper: PMID 210882922011
- Who
- Patients with ESRD or advanced chronic kidney disease (creatinine clearance below 30 ml/min), seven randomized trials
- Dose studied
- not reported
When pooling the seven trials, folic acid therapy reduced the risk of CVD by 15% (RR, 0.85; 95% CI, 0.76 to 0.96; P = 0.009).”
Quoted verbatim from Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: a meta-analysis.meta-analysisPermalink - All-site cancer incidencecontestedMoved: raisesEvidence: Very limitedPaper: PMID 361566602022
- Who
- Children of mothers with epilepsy who filled antiseizure medication prescriptions (Denmark, Norway, Sweden registers); prenatal exposure to filled prescriptions of high-dose folic acid (1 mg or 5 mg tablets) versus none; subgroup of mothers with epilepsy using antiseizure medication, cancer before age 20
- Dose studied
- high-dose folic acid, at least 1 filled prescription of 1 mg or 5 mg tablets between 90 days before pregnancy and birth
In children of mothers with epilepsy who filled prescriptions for ASM, a 3.0-fold (95% CI, 1.1-fold to 7.9-fold) increased risk of childhood cancer associated with exposure to high-dose folic acid was observed.”
Quoted verbatim from Cancer Risk in Children of Mothers With Epilepsy and High-Dose Folic Acid Use During Pregnancy.cohortPermalink - Gestational hypertension incidenceMoved: no difference foundEffect, as reportedRR1.03[0.98 to 1.09]Evidence: Very limitedPaper: PMID 262604062016
- Who
- Pregnant women in prospective studies of periconceptional folic acid alone
- Dose studied
- not reported
Pooled results indicated that folic acid fortification alone was not associated with the occurrence of gestational hypertension [relative risk (RR) = 1.03, 95% confidence interval (CI): 0.98-1.09, P = 0.267] and pre-eclampsia (RR = 0.99, 95% CI: 0.90-1.08, P = 0.738).”
Quoted verbatim from Periconceptional folic acid fortification for the risk of gestational hypertension and pre-eclampsia: a meta-analysis of prospective studies.meta-analysisPermalink - Pre-eclampsia incidenceMoved: no difference foundEffect, as reportedRR0.99[0.9 to 1.08]Evidence: Very limitedPaper: PMID 262604062016
- Who
- Pregnant women in prospective studies of periconceptional folic acid alone
- Dose studied
- not reported
Pooled results indicated that folic acid fortification alone was not associated with the occurrence of gestational hypertension [relative risk (RR) = 1.03, 95% confidence interval (CI): 0.98-1.09, P = 0.267] and pre-eclampsia (RR = 0.99, 95% CI: 0.90-1.08, P = 0.738).”
Quoted verbatim from Periconceptional folic acid fortification for the risk of gestational hypertension and pre-eclampsia: a meta-analysis of prospective studies.meta-analysisPermalink - Mean arterial pressureMoved: lowersEvidence: Very limitedPaper: PMID 158931702005
- Who
- Patients with ischemic heart disease, acute effect after a single oral dose
- Dose studied
- 30 mg folic acid single oral dose vs placebo
Folate was associated with a reduction in mean arterial pressure (100 +/- 12 mm Hg vs. 96 +/- 11 mm Hg, placebo vs. folate, p < 0.03).”
Quoted verbatim from High-dose folic acid acutely improves coronary vasodilator function in patients with coronary artery disease.crossoverPermalink - Colorectal adenoma recurrence after polypectomycontestedMoved: lowersEvidence: Very limitedPaper: PMID 186802282008
- Who
- Patients with colorectal adenomas at a VA Medical Center, polyps removed at baseline colonoscopy
- Dose studied
- 5 mg folic acid daily vs matched placebo for 3 years
High dose folic acid supplementation is associated with a significant reduction in the recurrence of colonic adenomas suggesting that folic acid may be an effective chemopreventive agent for colorectal neoplasia.”
Quoted verbatim from Folic acid supplementation inhibits recurrence of colorectal adenomas: a randomized chemoprevention trial.RCTPermalink - Colorectal adenoma recurrence after polypectomycontestedMoved: no difference foundEffect, as reportedRR0.82[0.59 to 1.13]Evidence: Very limitedPaper: PMID 198644092009
- Who
- Participants of the Health Professionals Follow-Up Study and Nurses' Health Study with prior adenoma, randomised to folic acid or placebo; whole-population primary endpoint
- Dose studied
- 1 mg/d
Incidence of at least one recurrent adenoma was not significantly associated with folic acid supplementation [relative risk (RR): 0.82; 95% CI: 0.59,1.13; P = 0.22].”
Quoted verbatim from A randomized trial on folic acid supplementation and risk of recurrent colorectal adenoma.RCTPermalink - Preterm birth incidenceMoved: no difference foundEffect, as reportedRR1.01[0.73 to 1.38]Evidence: Very limitedreplicated ×1Paper: PMID 235435472013
- Who
- Pregnant women in randomised trials of oral folic acid alone or with other micronutrients versus no folic acid · n = 2,959
- Dose studied
- not reported
This review found that folic acid supplementation has no impact on pregnancy outcomes such as preterm birth (risk ratio (RR) 1.01, 95% confidence interval (CI) 0.73 to 1.38; three studies, 2959 participants), and stillbirths/neonatal deaths (RR 1.33, 95% CI 0.96 to 1.85; three studies, 3110 participants).”
Quoted verbatim from Folic acid supplementation during pregnancy for maternal health and pregnancy outcomes.meta-analysisPermalink
No row matches these filters.
No dose is advised.